BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

A healthy biotech ecosystem comprises a continuum from big pharma and bellwether biotechs at the top to private newcos at the bottom, with a mixture of liquidity events -- predominantly M&A -- to reward investors....
BC Week In Review | Aug 10, 2015
Company News

Intercell, Novartis deal

Valneva SE (Euronext:VLA; VSE:VLA, Lyon, France) is terminating its marketing and distribution agreement with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) for Japanese Encephalitis vaccine Ixiaro . Valneva will regain rights to sell the product worldwide, excluding...
BC Week In Review | Apr 14, 2014
Clinical News

IC43: Phase II/III ongoing

This quarter, Valneva plans to resume enrollment of an additional 400 ventilated intensive care unit (ICU) patients in a double-blind, placebo-controlled, European Phase II/III trial evaluating 2 doses of IC43 plus hospitals' choice of standard...
BC Week In Review | Mar 3, 2014
Company News

Valneva, Sanofi deal

Valneva and Sanofi's Sanofi Pasteur vaccines division added a fourth mAb discovery program to a 2010 deal granting Sanofi Pasteur exclusive access to Valneva's VivaScreen technology to discover human mAbs to treat and prevent nosocomial...
BC Week In Review | Nov 18, 2013
Clinical News

AERAS-456: Phase I/IIa started

Not-for-profit Aeras and the Danish government institute said the South African Tuberculosis Vaccine Initiative (SATVI) began a 2-part, double-blind, South African Phase I/IIa trial to evaluate 3 doses of AERAS-456 containing 5, 15 or 50...
BC Week In Review | Nov 4, 2013
Clinical News

IC43: Phase II/III halted

Valneva halted enrollment in a double-blind, placebo-controlled, European Phase II/III trial evaluating 2 doses of IC43 plus hospitals' choice of standard of care (SOC) after a DMC interim analysis of 394 patients met the pre-specified...
BC Extra | Nov 1, 2013
Clinical News

Valneva falls on IC43 vaccine trial update

Valneva SE (Euronext:VLA; VSE:VLA) slid EUR 0.65 (12%) to EUR 4.80 on Thursday after an interim analysis by a DMC found the company's IC43 vaccine met the pre-specified criterion for futility on the primary endpoint...
BC Week In Review | Oct 7, 2013
Clinical News

C: Phase Ib data

Valneva said data from the Phase Ib portion of an open-label, dose-escalation, Austrian and Hungarian Phase I trial in 81 healthy volunteers >65 years of age showed that 4 vaccinations with 75 and 200 µg...
BC Week In Review | Jul 29, 2013
Clinical News

Ixiaro regulatory update

The World Health Organization (WHO) awarded prequalification to Biological E's Japanese Encephalitis (JE) vaccine for worldwide use in adults. Biological E expects WHO to extend the prequalification to include pediatric use by year end. The...
BC Week In Review | Jul 15, 2013
Clinical News

Ixiaro regulatory update

Valneva said the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) expanded its recommendation for Ixiaro Japanese Encephalitis (JE) vaccine to include use in pediatric individuals ages >=2 months....
Items per page:
1 - 10 of 81
BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

A healthy biotech ecosystem comprises a continuum from big pharma and bellwether biotechs at the top to private newcos at the bottom, with a mixture of liquidity events -- predominantly M&A -- to reward investors....
BC Week In Review | Aug 10, 2015
Company News

Intercell, Novartis deal

Valneva SE (Euronext:VLA; VSE:VLA, Lyon, France) is terminating its marketing and distribution agreement with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) for Japanese Encephalitis vaccine Ixiaro . Valneva will regain rights to sell the product worldwide, excluding...
BC Week In Review | Apr 14, 2014
Clinical News

IC43: Phase II/III ongoing

This quarter, Valneva plans to resume enrollment of an additional 400 ventilated intensive care unit (ICU) patients in a double-blind, placebo-controlled, European Phase II/III trial evaluating 2 doses of IC43 plus hospitals' choice of standard...
BC Week In Review | Mar 3, 2014
Company News

Valneva, Sanofi deal

Valneva and Sanofi's Sanofi Pasteur vaccines division added a fourth mAb discovery program to a 2010 deal granting Sanofi Pasteur exclusive access to Valneva's VivaScreen technology to discover human mAbs to treat and prevent nosocomial...
BC Week In Review | Nov 18, 2013
Clinical News

AERAS-456: Phase I/IIa started

Not-for-profit Aeras and the Danish government institute said the South African Tuberculosis Vaccine Initiative (SATVI) began a 2-part, double-blind, South African Phase I/IIa trial to evaluate 3 doses of AERAS-456 containing 5, 15 or 50...
BC Week In Review | Nov 4, 2013
Clinical News

IC43: Phase II/III halted

Valneva halted enrollment in a double-blind, placebo-controlled, European Phase II/III trial evaluating 2 doses of IC43 plus hospitals' choice of standard of care (SOC) after a DMC interim analysis of 394 patients met the pre-specified...
BC Extra | Nov 1, 2013
Clinical News

Valneva falls on IC43 vaccine trial update

Valneva SE (Euronext:VLA; VSE:VLA) slid EUR 0.65 (12%) to EUR 4.80 on Thursday after an interim analysis by a DMC found the company's IC43 vaccine met the pre-specified criterion for futility on the primary endpoint...
BC Week In Review | Oct 7, 2013
Clinical News

C: Phase Ib data

Valneva said data from the Phase Ib portion of an open-label, dose-escalation, Austrian and Hungarian Phase I trial in 81 healthy volunteers >65 years of age showed that 4 vaccinations with 75 and 200 µg...
BC Week In Review | Jul 29, 2013
Clinical News

Ixiaro regulatory update

The World Health Organization (WHO) awarded prequalification to Biological E's Japanese Encephalitis (JE) vaccine for worldwide use in adults. Biological E expects WHO to extend the prequalification to include pediatric use by year end. The...
BC Week In Review | Jul 15, 2013
Clinical News

Ixiaro regulatory update

Valneva said the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) expanded its recommendation for Ixiaro Japanese Encephalitis (JE) vaccine to include use in pediatric individuals ages >=2 months....
Items per page:
1 - 10 of 81